Optimizing Anticoagulant Therapy in Atrial Fibrillation: A Comparative Analysis of Warfarin and Direct Oral Anticoagulants
Received Date: Dec 01, 2024 / Published Date: Dec 31, 2024
Abstract
Abstract Anticoagulant therapy is pivotal in managing atrial fibrillation (AF) to prevent stroke and systemic embolism. This article presents a comparative analysis of warfarin and direct oral anticoagulants (DOACs) in optimizing anticoagulant therapy for AF. While warfarin has been the standard therapy for decades, DOACs offer advantages such as predictable anticoagulant effects, fewer drug interactions, and simplified dosing regimens. Clinical trials have shown non-inferiority or superiority of DOACs over warfarin in stroke prevention with a lower risk of intracranial hemorrhage. However, considerations such as cost and patient-specific factors should guide treatment selection. This analysis aims to assist clinicians in making informed decisions to improve outcomes in AF management.
Citation: Zou G (2024) Optimizing Anticoagulant Therapy in Atrial Fibrillation:A Comparative Analysis of Warfarin and Direct Oral Anticoagulants. World JPharmacol Toxicol 7: 252.
Copyright: © 2024 Zou G. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.
Select your language of interest to view the total content in your interested language
Share This Article
51ºÚÁϳԹÏÍø Journals
Article Usage
- Total views: 752
- [From(publication date): 0-2024 - Jun 23, 2025]
- Breakdown by view type
- HTML page views: 529
- PDF downloads: 223
